YD Bio (NASDAQ:YDES) Upgraded by Wall Street Zen to “Hold” Rating

Wall Street Zen upgraded shares of YD Bio (NASDAQ:YDES) from a sell rating to a hold rating in a research note released on Saturday morning.

Separately, Weiss Ratings reiterated a “sell (d+)” rating on shares of YD Bio in a research note on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has an average rating of “Sell”.

YD Bio Stock Performance

NASDAQ:YDES opened at $8.58 on Friday. YD Bio has a 1-year low of $7.20 and a 1-year high of $25.00. The firm has a fifty day moving average price of $11.05.

Institutional Trading of YD Bio

A hedge fund recently raised its stake in YD Bio stock. Geode Capital Management LLC increased its stake in shares of YD Bio Limited (NASDAQ:YDES) by 10.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 58,363 shares of the biotechnology company’s stock after buying an additional 5,292 shares during the period. Geode Capital Management LLC owned about 0.08% of YD Bio worth $711,000 as of its most recent filing with the Securities and Exchange Commission.

About YD Bio

YD Bio Limited is a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations.